Table 1 Characteristics of the patients

Male

36 (85.7)

Female

6 (14.3)

Age

<65

15 (35.7)

≥ 65

27 (64.3)

Smoking

Yes

14 (33.3)

No

28 (66.7)

ECOG

0

30 (71.4)

1

12 (28.6)

Primary site

Bladder

26 (61.9)

Renal Pelvis and Ureter

16(38.1)

Metastatic site

Non-occurrence

3 (7.1)

Lung

8 (19.0)

Liver

4 (9.5)

Bone

5 (11.9)

Lymph node

14 (33.3)

Adjacent tissues and organs

13 (31.0)

Prior surgery

Yes

35 (83.3)

 Radical

26

 Local

9

No

7 (16.7)

Prior chemotherapy or immunotherapy

Yes

15 (35.7)

No

27 (64.3)

HER2

IHC 0

1 (2.4)

IHC 1+

13 (31.0)

IHC 2 + FISH-

16 (38.1)

IHC 2 + FISH+

4 (9.5)

IHC 3+

8 (19.0)

PD-L1

Positive

13 (40.6)

Negative

19 (59.4)

HER2&PD-L1

HER2 IHC (2+/3+), PD-L1(+)

11 (26.2)

HER2 IHC (2+/3+), PD-L1(-)

11 (26.2)

HER2 IHC (1+), PD-L1(+)

2 (4.8)

HER2 IHC (1+), PD-L1(-)

8 (19.0)

RC48 treatment lines

Neoadjuvant therapy

8 (19.0)

First-line therapy

19 (45.2)

Second- or later-line therapy

15 (35.7)